MYOMO INC. NEW DL-,0001

Myomo reported Q2 revenue of $11.7 million, up 21% year over year, driven by a 19% increase in recognized MyoPro units to 211 and a record 255 orders. Recurring referral sources now account for 53% of quarterly revenue (vs. 26% a year earlier) as the company expands its referral network above 300 sites. Gross margin improved to 72.1% and operating loss narrowed to $2.3 million; adjusted EBITDA loss fell to $800,000. Management raised full-year 2026 revenue guidance to $45 million–$47 million, expects Q3 revenue of $11.5 million–$12 million, and forecasts second-half cash burn below $2 million. » More on finance.yahoo.com

Myomo reported a 21% rise in Q2 revenue to $11.7 million, a reduced net loss of $0.09 per share and a markedly improved gross margin of 72.1%. The quarter was supported by a record order intake of 255 MyoPro units and 211 devices delivered. The company raised its 2026 revenue guidance to $45–47 million and signaled progress on operating leverage. The stock rose modestly in after-hours trading following the results. » More on de.investing.com

Myomo reported better-than-expected Q1 results: EPS -$0.07 (expected -$0.12) and revenue $10.1 million (expected $9.24 million). Revenue rose 3% year-on-year, gross margin improved to 68.2%, and the company shipped 172 MyoPro units. For Q2 Myomo forecasts revenue between $10.3 million and $10.8 million; nevertheless the stock fell after-hours, initially by 2.98% and then declined further. » More on de.investing.com